Learn more about Buprenorphine and its use in pain and substance use disorders.
Share your latest research and clinical experiences!
Cutting-edge information about an alternative to traditional strong opioids!
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Buprenorphine in Medicine (Bupe2024) is a “virtual resource” that is an extension of Journal of Opioid Management’s Special Issue on Buprenorphine. BUPE2024 is a resource for those looking to learn about this interesting molecule and apply it in clinical practice for pain management.
Call for Presentations! For full details, please consult our Call for Presentations document located here.
CMEs for BUPE2024 will go live on December 15th, 2023. Previous BUPE2021/2022 Presentations are available. NOTE, you will not be able to claim CMEs but the video education is still worth the price! Plus, attendees will receive a copy of our Journal of Opioid Management special issue on Buprenorphine. It is part of your registration and available for download immediately after you register.
Sign up today! Take advantage of great content, great presenters, our special issue on buprenorphine and get continuing education credit too!
Buprenorphine was conceived by Alan Cowan as a safer opioid analgesic relative to morphine which reduced dysphoria and craving by blocking dysphoria through blocking kappa opioid receptors. It was later found to have a ceiling on respiratory depression demonstrated by the Leiden group of opioid researchers. Its utility as a safer long-acting opioid agonist relative to methadone lead to its adoption into maintenance therapy for those battling substance use disorders. In 2019 the Department of Health and Human Services pain management guidelines recommended the use of buprenorphine, a schedule III opioid, before considering schedule II opioids in managing moderate to severe pain. As the field of pain medicine turns away from traditional strong opioids, alternative options in pain management now include buprenorphine as a frontline opioid analgesic when oral analgesia is necessary. Join us as we explore the expanding role of Buprenorphine in medicine and pain management.
BUPE2024 is a virtual resource. You can browse the great presentation and learn at your pace! Join us!
I am looking forward to a rational discussion about Buprenorphine in pain management and those battling opioid use disorders!
